W
William Small
Researcher at Loyola University Chicago
Publications - 423
Citations - 15241
William Small is an academic researcher from Loyola University Chicago. The author has contributed to research in topics: Radiation therapy & Brachytherapy. The author has an hindex of 56, co-authored 396 publications receiving 12744 citations. Previous affiliations of William Small include University of Hong Kong & University of Chicago.
Papers
More filters
Journal ArticleDOI
American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy.
William Small,Sushil Beriwal,D. Jeffrey Demanes,Kathryn E. Dusenbery,Patricia J. Eifel,Beth Erickson,Ellen L. Jones,Jason Rownd,Jennifer F. De Los Santos,Akila N. Viswanathan,David K. Gaffney +10 more
TL;DR: Recommendations are made that applicator selection should be based on patient anatomy, target volume geometry, and physician judgment, and the dose prescription point should be clearly specified for postoperative adjuvant vaginal cuff brachytherapy.
Journal ArticleDOI
Adverse reactions to intravenous iodinated contrast media: a primer for radiologists
TL;DR: The radiologist can play a pivotal role by being aware of predisposing factors, clinical presentation, and management of adverse reactions to contrast media, which can range from transient minor reactions to life-threatening severe reactions.
Journal ArticleDOI
Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer.
Ann H. Klopp,Jennifer Moughan,Lorraine Portelance,Brigitte Miller,Mohammad Salehpour,Evangeline Hildebrandt,Jenny Nuanjing,David D'Souza,Luis Souhami,William Small,R. Gaur,Anuja Jhingran +11 more
TL;DR: Evaluation and limitation of the volume of bone marrow treated with pelvic IMRT is warranted in patients receiving concurrent chemotherapy, and Pelvic IMRT with weekly cisplatin is associated with low rates of HT and high rates of weekly cis Platin use.
Journal ArticleDOI
Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: A Phase 2 Study
Jeffrey M. Hardacre,Mary F. Mulcahy,William Small,Mark S. Talamonti,Jennifer Obel,Smitha S. Krishnamurthi,Caio S. Rocha-Lima,Howard Safran,Heinz Joseph Lenz,E. Gabriela Chiorean +9 more
TL;DR: The addition of algenpantucel-L to standard adjuvant therapy for resected pancreatic cancer may improve survival and a multi-institutional, phase 3 study is ongoing.
Journal ArticleDOI
International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG).
Akila N. Viswanathan,Carien L. Creutzberg,Peter S. Craighead,Mary McCormack,Takafumi Toita,Kailash Narayan,Nicholas S. Reed,Harry J. Long,Hak Jae Kim,Christian Marth,Jacob Christian Lindegaard,Annmarie Cerrotta,William Small,Edward L. Trimble +13 more
TL;DR: Although fractionation patterns may vary, the overall mean doses administered for cervical cancer are similar in Australia/New Zealand, Europe, and North America, with practitioners in Japan administering a significantly lower external-beam dose but higher brachytherapy dose to the cervix.